This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thermo Fisher (TMO) Launches Surveillance Tool for COVID-19
by Zacks Equity Research
The latest launch of surveillance solution is an extremely timely development by Thermo Fisher (TMO) and is expected to witness fast market adoption.
J&J's (JNJ) Pharma Unit & COVID-19 Vaccine Key to 2021 Growth
by Zacks Equity Research
J&J's (JNJ) Pharma unit is performing above-market levels, helped by new drugs and label expansion of blockbuster drugs, Imbruvica, Darzalex & Stelara. Its COVID-19 vaccine is expected to contribute to sales growth.
Bull of the Day: Owens and Minor (OMI)
by David Borun
This medical logistics company made big gains in 2020 - and is poised to keep heading higher.
Pfizer (PFE) Gets Unfavorable Votes from FDA Panel for Tanezumab
by Zacks Equity Research
Pfizer (PFE) and Eli Lilly receive FDA Joint Advisory Committee's vote results for tanezumab being developed for treating osteoarthritis pain. The committee voted 1 in favor and 19 against tanezumab.
The Zacks Analyst Blog Highlights: Pfizer, UnitedHealth Group, Centene Corp, Cigna Corp and AMN Healthcare Services
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, UnitedHealth Group, Centene Corp, Cigna Corp and AMN Healthcare Services
AstraZeneca (AZN) Reports New Efficacy Data on COVID-19 Vaccine
by Zacks Equity Research
AstraZeneca (AZN) reports new efficacy data for its COVID-19 vaccine in the Unites States following criticism for providing outdated data.
4 Stocks That Continue to Gain From Telehealth Offerings
by Zacks Equity Research
We take a sneak peek into four telehealth stocks that are well-poised for growth on their robust digital services suite.
Myovant's (MYOV) Data on Relugolix for Uterine Fibroids Positive
by Zacks Equity Research
Myovant (MYOV) and partner Pfizer report positive data from the phase III LIBERTY study evaluating relugolix combination therapy for treating women with uterine fibroids.
Pfizer (PFE) Begins Clinical Study on COVID-19 Antiviral Pill
by Zacks Equity Research
Pfizer (PFE) starts an early-stage U.S. study on an oral COVID-19 antiviral candidate.
Merck (MRK) Gets FDA Nod for Keytruda in Esophageal Cancer
by Zacks Equity Research
The FDA approves Merck's (MRK) anti-PD-1 therapy, Keytruda in combination with chemotherapy, for the first-line treatment of esophageal and gastroesophageal junction carcinoma.
Humana (HUM), Inovalon Expands Ties for Vaccine Adherence Efforts
by Zacks Equity Research
Humana (HUM) extends collaboration with Inovalon, which highlights the company's focus on vaccine adherence for helping its health plan members.
AstraZeneca (AZN) COVID-19 Vaccine Data May Be Outdated Per NIH
by Zacks Equity Research
NIH's Data Safety Monitoring Board questions AstraZeneca's (AZN) COVID-19 vaccine data from its late-stage U.S. study.
Will the Fourth COVID-19 Vaccine in U.S. Get FDA Nod Soon?
by Kinjel Shah
Interim data from a U.S. late-stage study on AstraZeneca's (AZN) COVID-19 vaccine shows that the candidate was, on average, about 79% effective in preventing COVID-19.
5 S&P 500 Stocks That Zoomed 200% Plus From Pandemic Lows
by Sweta Killa
After touching a low of 2,191 on Mar 23, 2020, the S&P 500 staged a strong comeback and is on track to hit a new milestone of 4,000.
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $36, moving +1.32% from the previous trading session.
Exelixis (EXEL) Inks Collaboration Deal to Test XL092 Combo in UC
by Zacks Equity Research
Exelixis (EXEL) signs a collaboration and supply agreement with Merck KGaA and Pfizer to investigate XL092 in combination with Bavencio for treating various forms of urothelial carcinoma.
1-Year Tour From Market Crash to Boom: 5 Top ETFs
by Sweta Killa
The stock market staged a strong rebound from the lows and is currently hitting new highs with the major bourses crossing new milestones.
AbbVie (ABBV) Down as FDA Extends Review of Rinvoq sNDA
by Zacks Equity Research
The FDA extends the review period of AbbVie's (ABBV) label expansion application for Rinvoq in active psoriatic arthritis by three months.
Moderna (MRNA) Begins Pediatric Study on COVID-19 Vaccine
by Zacks Equity Research
Moderna is developing its COVID-19 vaccine, mRNA-1273, for different patient populations. It is also developing booster vaccine candidates as well as a next-generation COVID vaccine.
Merck (MRK) VHL-Linked Kidney Cancer Drug Gets FDA Priority Tag
by Zacks Equity Research
The FDA grants Merck's (MRK) NDA for belzutifan priority review status to treat von Hippel-Lindau disease-associated renal-cell carcinoma.
AstraZeneca (AZN) COVID-19 Shot Faces Doubts Over Blood Clots
by Zacks Equity Research
The EMA will continue to investigate whether AstraZeneca's (AZN) COVID-19 vaccine was the cause of the blood clot events or if these were due to other reasons.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $35.83, marking a +1.19% move from the previous day.
Lilly (LLY) Down as Alzheimer's Drug Fails Investor Expectation
by Zacks Equity Research
Eli Lilly (LLY) announces detailed data on secondary endpoints of its mid-stage study evaluating its antibody candidate, donanemab, in patients with early symptomatic Alzheimer's disease.
Solid Biosciences (SLDB) Announces DMD Study Data, Stock Down
by Zacks Equity Research
Solid Biosciences' (SLDB) lead gene therapy candidate achieves positive improvements in DMD patients. However, it fails to cheer investors.
Corcept (CORT) Begins Adrenal Cancer Study on Relacorilant
by Zacks Equity Research
Corcept (CORT) commences phase Ib study on relacorilant in combination with Keytruda for treating patients with adrenal cancer with cortisol excess.